Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918314 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL9921641 | 0.88 | ALDH1A1 (0.46) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL9920478 | 0.86 | ALDH1A1 (0.52) | ALDH1A1HPGDLMNAL3MBTL3L3MBTL1 | |
| SCHEMBL12832911 | 0.86 | ALDH1A1 (0.52) | ALDH1A1HPGDLMNAL3MBTL3L3MBTL1 | |
| SCHEMBL9921710 | 0.85 | HPGD (0.56) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL14625164 | 0.81 | HPGD (0.57) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL328077 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL279955 | 0.77 | HPGD (0.56) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL279839 | 0.75 | ALDH1A1 (0.53) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL280089 | 0.73 | ALDH1A1 (0.51) | ALDH1A1HPGDLMNAGAASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 1632/4885HPGD 858/4885LMNA 4792/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ALDH1A1 1507/4885HPGD 545/4885LMNA 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.